Author

Catherine Domenger

Observed names: CATHERINE DOMENGER, Domenger, Catherine

Institution: Sanofi (France)

Observed institution: Sanofi (France)

OpenAlex ID: A5111955288

Factors Associated With Diabetes-Specific Health-Related Quality of Life in Youth With Type 1 Diabetes: The Global TEENs Study

2017 · Barbara J. Anderson, Lori M. Laffel, et al. · Diabetes Care · 170

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

2017 · Lawrence A. Leiter, Bertrand Cariou, et al. · Diabetes Obesity and Metabolism · 139

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

2018 · Kausik K. Ray, Lawrence A. Leiter, et al. · Diabetes Obesity and Metabolism · 102

Impact of diabetes education and self-management on the quality of care for people with type 1 diabetes mellitus in the Middle East (the International Diabetes Mellitus Practices Study, IDMPS)

2018 · Juan José Gagliardino, Jean-Marc Chantelot, et al. · Diabetes Research and Clinical Practice · 60

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

2019 · Kausik K. Ray, Stefano Del Prato, et al. · Cardiovascular Diabetology · 43

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

2020 · Helen M. Colhoun, Lawrence A. Leiter, et al. · Cardiovascular Diabetology · 33

Half-Unit Insulin Pens: Disease Management in Patients With Diabetes Who Are Sensitive to Insulin

2016 · David C. Klonoff, Irina Nayberg, et al. · Journal of Diabetes Science and Technology · 18

Diabetes education and health insurance: How they affect the quality of care provided to people with type 1 diabetes in Latin America. Data from the International Diabetes Mellitus Practices Study (IDMPS)

2018 · Juan José Gagliardino, Jean-Marc Chantelot, et al. · Diabetes Research and Clinical Practice · 14

Functional Evaluation of the Reusable JuniorSTAR ® Half-Unit Insulin Pen

2015 · David Klonoff, Irina Nayberg, et al. · Journal of Diabetes Science and Technology · 6

Evaluation of the JuniorSTAR® Half-unit Insulin Pen in Young People with Type 1 Diabetes – User Perspectives

2010 · David Klonoff, Irina Nayberg, et al. · touchREVIEWS in Endocrinology · 5

Erratum. Factors Associated With Diabetes-Specific Health-Related Quality of Life in Youth With Type 1 Diabetes: The Global TEENs Study. Diabetes Care 2017;40:1002—1009

2018 · Barbara J. Anderson, Lori M. Laffel, et al. · Diabetes Care · 2

Alirocumab offers superior benefits to usual care in treating high-risk patients with type 2 diabetes

2020 · Kausik K. Ray, Lawrence A. Leiter, et al. · 1

175-OR: Effect of Alirocumab in Individuals with Type 2 Diabetes and High Triglycerides and Low High-Density Lipoprotein Cholesterol

2019 · HELEN M. COLHOUN, LAWRENCE A. LEITER, et al. · Diabetes · 1

Glycaemic Control and Acute Complications in European Children, Adolescents, and Young Adults With Type 1 Diabetes in the Teens Study

2014 · Moshe Phillip, Lori M. Laffel, et al. · ESPE 2014 · 1

Alirocumab Add-on Therapy Versus Control in Individuals with Type 2 DM and ASCVD: ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN

2018 · Kausik K. Ray, Stefano Del Prato, et al. · Atherosclerosis Supplements

Alirocumab chez les sujets diabÃ©tiques de type 1 ou type 2 sous insuline et Ã haut risque cardiovasculaire: rÃ©sultats de lâÃ©tude ODYSSEY DM-INSULIN

2018 · Bertrand Cariou, Lawrence A. Leiter, et al.

Works count: 19

Citation count: 595

H-index: 8

I10-index: 8